| VIS ID | Virus | Ensembl ID | Gene Type | Target Gene | Oncogene | Tumor Suppressor Gene | NCBI ID | Uniprot ID |
|---|---|---|---|---|---|---|---|---|
| TVIS30001246 | HIV | ENSG00000198851.10 | protein_coding | CD3E | No | No | 916 | P07766 |
| TVIS30001964 | HIV | ENSG00000198851.10 | protein_coding | CD3E | No | No | 916 | P07766 |
| TVIS30011637 | HIV | ENSG00000198851.10 | protein_coding | CD3E | No | No | 916 | P07766 |
| TVIS30031388 | HIV | ENSG00000198851.10 | protein_coding | CD3E | No | No | 916 | P07766 |
Target Gene Table
▼
TCGA Plot Options
▼
Drug Information
▼
| Gene | CD3E |
|---|---|
| DrugBank ID | DB16672 |
| Drug Name | Epcoritamab |
| Target ID | BE0000274 |
| UniProt ID | P07766 |
| Regulation Type | binder |
| PubMed IDs | 36548927 |
| Citations | Thieblemont C, Phillips T, Ghesquieres H, Cheah CY, Clausen MR, Cunningham D, Do YR, Feldman T, Gasiorowski R, Jurczak W, Kim TM, Lewis DJ, van der Poel M, Poon ML, Cota Stirner M, Kilavuz N, Chiu C, Chen M, Sacchi M, Elliott B, Ahmadi T, Hutchings M, Lugtenburg PJ: Epcoritamab, a Novel, Subcutaneous CD3xCD20 Bispecific T-Cell-Engaging Antibody, in Relapsed or Refractory Large B-Cell Lymphoma: Dose Expansion in a Phase I/II Trial. J Clin Oncol. 2023 Apr 20;41(12):2238-2247. doi: 10.1200/JCO.22.01725. Epub 2022 Dec 22. |
| Groups | Approved; Investigational |
| Direct Classification | Peptides |
| SMILES | |
| Pathways | |
| PharmGKB | |
| ChEMBL |
